Core Insights - The combination of AFM24 and atezolizumab shows promising efficacy in heavily pretreated non-small cell lung cancer (NSCLC) patients, with objective responses observed in both EGFR wild-type and mutant cohorts [1][2][3][4] Summary by Sections Efficacy Data - In the EGFR wild-type cohort, 4 objective responses were recorded, including 1 complete response (CR) and 3 partial responses (PR), with a disease control rate of 71% and a median progression-free survival (PFS) of 5.9 months [2][4] - In the EGFR mutant cohort, the combination therapy resulted in 1 CR, 3 PRs, and 6 patients with stable disease (SD), indicating potential synergistic effects [3][4] Safety Profile - The combination therapy demonstrated a manageable safety profile, with side effects consistent with known profiles of the individual agents, primarily mild to moderate infusion-related reactions and transient increases in liver enzymes [3][4] Future Developments - The study plans to enroll up to 40 patients in the EGFR wild-type cohort and 25 patients in the EGFR mutant cohort, with ongoing recruitment and further updates expected in the second half of 2024 [4] Company Overview - Affimed N.V. is a clinical-stage immuno-oncology company focused on harnessing the innate immune system to combat cancer, utilizing its proprietary ROCK® platform to develop innate cell engagers (ICE®) [6][7]

Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with EGFR wild-type and EGFR mutant advanced/metastatic cancers in the ongoing AFM24-102 phase 1/2a studyThe FDA's Fast Track designation was granted after its review of the initial efficacy data of the EGFR wild-type cohort from the AFM24-102 studyFast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious condi ...

Core Viewpoint - Affimed N.V. is set to hold its 2024 Annual General Meeting of Shareholders on June 26, 2024, in Amsterdam, focusing on its commitment to advancing immuno-oncology therapies for cancer treatment [1]. Company Overview - Affimed N.V. is a clinical-stage immuno-oncology company dedicated to enhancing patients' innate ability to combat cancer through its innovative innate cell engagers (ICE®) [2]. - The company's proprietary ROCK® platform is utilized to create customized molecules that harness the innate immune system to target and eliminate various hematologic and solid tumors [2]. - Affimed is headquartered in Mannheim, Germany, and is led by a team of experienced professionals in biotechnology and pharmaceuticals, aiming to prevent cancer from disrupting patients' lives [2].

Core Insights - The article discusses the high-risk, high-reward nature of investing in penny biotech stocks, emphasizing the complexities and potential failures in drug development and commercialization [1][2]. Company Summaries FibroGen (FGEN) - FibroGen is advancing multiple drug candidates, including Pamrevlumab and Roxadustat, with the former in Phase 3 trials for pancreatic cancer and the latter approved for anemia in chronic kidney disease [3][4]. - The company reported revenues of approximately $56 million in Q1, up from $36 million year-over-year, and reduced net losses from $76.7 million to just below $32 million [4]. Nuvectis Pharma (NVCT) - Nuvectis Pharma is a pre-revenue biotech firm with shares trading at $6.21, and an analyst predicts a future value of $22 [6]. - The lead drug NXP800 has received fast-track designation from the FDA for treating platinum-resistant ARID1a-mutated ovarian cancer and is currently in Phase 1b studies [7]. Relmada Therapeutics (RLMD) - Relmada is focused on central nervous system diseases, particularly major depressive disorder, with its lead drug REL-1017 in late-stage development [8][9]. - The company trades at $3.04, with an analyst target price of $25, despite being in pre-revenue stages [9]. Anixa Biosciences (ANIX) - Anixa develops treatments for ovarian and breast cancer, with shares trading below $3 and a target price of $12 [11]. - The company is conducting a CAR-T clinical trial for ovarian cancer and has expanded its partnership with the Cleveland Clinic for cancer vaccine development [12]. Genenta Science (GNTA) - Genenta is developing a stem cell platform for treating solid tumors, with shares trading at $3.30 and a consensus target price of $20 [13][14]. - The company has limited revenue generation and is based in Italy, which may pose challenges in information availability [13]. Affimed (AFMD) - Affimed focuses on lymphoma treatments and has streamlined operations by reducing its workforce by 50% [16]. - The company has three lead candidate programs progressing in 2023, with a current share price of just over $4 and a target price of $32 [16]. Lipocine (LPCN) - Lipocine operates in the obesity management space, with shares trading at $6.89 and a target price of $33 [17]. - The company reported a net income of $3.5 million in the latest quarter, reversing a loss from the previous year, and is developing treatments across various disease areas [18].

Core Insights - The combination of AFM24 and atezolizumab in patients with metastatic EGFR wild-type NSCLC showed a disease control rate of 73.3% with 4 objective responses, including 1 complete response and 3 partial responses [1][2] - The median progression-free survival for the treatment was reported at 5.9 months, with 3 of the 4 responses ongoing as of the March 18, 2024 data cut-off [1][2] - The study will present its findings at the ASCO annual meeting on June 1, 2024, and a conference call will be held the same day to discuss updated results [1][4][5] Study Details - The AFM24-102 study involved 17 patients with EGFR wild-type NSCLC, of which 15 were evaluable for response [2] - All responders had previously shown resistance to checkpoint inhibitor treatments, indicating the potential of AFM24 combined with atezolizumab to enhance the cancer-immunity cycle [2][3] - The study aims to enroll up to 40 patients in the EGFR wild-type cohort and 25 patients in the EGFR mutant cohort [3] Treatment and Safety - AFM24 and atezolizumab were administered at their respective single-agent doses, and the treatment was well tolerated among heavily pretreated patients [3] - Side effects were consistent with known safety profiles, primarily mild to moderate infusion-related reactions and transient increases in liver enzymes [3] Company Overview - Affimed N.V. is a clinical-stage immuno-oncology company focused on leveraging the innate immune system to combat cancer through its proprietary ICE® platform [7][8] - The company is committed to developing therapies that enable a tumor-targeted approach to treat various hematologic and solid tumors [8]

Core Insights - The combination of AFM24 and atezolizumab in patients with metastatic EGFR wild-type NSCLC showed a disease control rate of 73.3%, with 11 out of 15 patients achieving disease control, including 4 objective responses (1 complete and 3 partial) [1][2] - The median progression-free survival for the treatment was reported at 5.9 months, with 3 of the 4 responses still ongoing as of the March 18, 2024 data cut-off [1][2] - The study results will be presented at the ASCO annual meeting on June 1, 2024, and a conference call will be held the same day to discuss updated results [1][4][5] Study Details - The AFM24-102 study involved 17 patients with EGFR wild-type NSCLC, with 15 being evaluable for response [2] - All responders had previously shown resistance to checkpoint inhibitor treatments, indicating the potential of AFM24 combined with atezolizumab to enhance the cancer-immunity cycle [2][3] - The study aims to enroll up to 40 patients in the EGFR wild-type cohort and 25 patients in the EGFR mutant cohort [3] Treatment Tolerability - The treatment was well tolerated among heavily pretreated patients, with side effects consistent with known safety profiles of the agents used [3] - The most common side effects included mild to moderate infusion-related reactions and transient increases in liver enzymes [3] Company Overview - Affimed N.V. is a clinical-stage immuno-oncology company focused on leveraging the innate immune system to combat cancer [8] - The company's proprietary ROCK® platform is used to develop its innate cell engagers (ICE®), which target a range of tumors [8] - Affimed is committed to advancing clinical development and exploring combination therapies to improve patient outcomes [3][8]

Group 1: Interest Rate Impact on Small-Cap Stocks - Analysts predict an interest rate cut by September, which may lead speculative capital to shift away from large-cap stocks, making small-cap stocks an attractive investment opportunity [1] - Small-cap stocks have been negatively impacted by rising interest rates in 2022 and 2023, particularly those of early-stage companies that are not yet profitable [1] - Despite the risks, small-cap stocks have the potential for significant gains, with a 10x return becoming more probable after a period of pressure [1] Group 2: Clean Energy Fuels (CLNE) - Clean Energy Fuels specializes in providing various forms of natural gas, including renewable natural gas, compressed natural gas, and liquefied natural gas [2] - Following the spike in natural gas prices due to geopolitical events, prices have since declined to levels not seen in over 20 years [2] - Demand for natural gas is expected to rise due to the power needs of data centers, which will benefit companies like Clean Energy Fuels [2] Group 3: Price Targets and Growth Potential - Analysts have set a consensus price target of $7.06 for CLNE stock, indicating a potential gain of over 155% in the next 12 months [3] - The long-term cycle of increased natural gas demand positions CLNE as a promising small-cap stock for future investment [3] Group 4: Bitdeer Technologies (BTDR) - Bitdeer Technologies is a Bitcoin mining company that has developed its own mining chip, enhancing operational efficiency and reducing supply chain risks [5] - Despite a 45% decline in BTDR stock this year, analysts have a consensus price target of $13.31, suggesting a potential return of 147% in the next 12 months [5] Group 5: Affimed (AFMD) - Affimed is a biotech company focused on cancer treatment through its Innate Cell Engager (ICE) molecules, with its lead candidate completing Phase 2 trials [6] - The company is funded through the first half of 2025, allowing it to advance clinical development [6] - Analysts have a consensus price target of $15.08 for AFMD, indicating a potential gain of 190%, with six out of seven analysts rating it as a "strong buy" [6]

分组1 - Shares of Affimed N.V. (AFMD) have gained 0.6% over the past four weeks, closing at $5.35, with a mean price target of $13.20 indicating a potential upside of 146.7% [1] - The average price targets range from a low of $5 to a high of $25, with a standard deviation of $8.87, suggesting variability in analyst estimates [1] - Analysts have shown increasing optimism about AFMD's earnings prospects, with a 23.5% increase in the Zacks Consensus Estimate for the current year due to three upward revisions [5][6] 分组2 - The Zacks Rank for AFMD is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [6] - While consensus price targets may not be reliable for predicting stock gains, they can indicate the direction of price movement, which appears to be a good guide [7]

The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted for poster presentation MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract presenting preliminary data from the phase 2 combination ...

Core Viewpoint - Affimed N.V. (AFMD) has shown a downtrend recently, losing 12% over the past week, but a hammer chart pattern suggests a potential trend reversal due to increased buying interest and support from bulls [1] Technical Analysis - The hammer chart pattern indicates a potential bottom in a downtrend, characterized by a small candle body and a long lower wick, suggesting that selling pressure may be subsiding [2][3] - This pattern typically forms when a stock opens lower, makes a new low, but then closes near or above its opening price, indicating a shift in control from bears to bulls [2][3] Fundamental Analysis - Recent upward revisions in earnings estimates for AFMD serve as a bullish indicator, with a 23.5% increase in the consensus EPS estimate over the last 30 days, reflecting analysts' optimism about the company's earnings performance [4] - AFMD holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which historically outperform the market [4] - The Zacks Rank is a reliable timing indicator, suggesting that AFMD's prospects are improving, further supporting the case for a potential turnaround [4]